$KRTL Holding Group Provides Corporate Update: SIGMA Integration, Regulatory Progress, and PCAOB Audit Engagement
https://www.otcmarkets.com/stock/KRTL/news/KR...?id=497103
KRTL Holding Group Inc. (OTC: KRTL) ("KRTL Holding" or the "Company"
today issued a corporate update summarizing recent operational milestones, strategic transactions, and its path forward in public company compliance.
In the third quarter of 2025, KRTL Holding successfully closed its strategic merger with Industria Químico-Farmacéutica SIGMA Corp., a Bolivian pharmaceutical manufacturer with over 50 years of continuous operation and a national reputation for quality manufacturing, public health alignment, and product innovation. The deal was finalized in September 2025, and initial integration steps are in process within the first 30 days, including organizational realignment, catalog assessment, and operational audits. The integration of SIGMA under the KRTL Biotech Inc. subsidiary marks a major advancement in the Company’s long-term strategy to build a scalable, international life sciences platform.
"The SIGMA transaction positions KRTL to be more than a U.S. holding company — it makes us an operating force in international pharma," said Cesar Herrera, CEO of KRTL Holding Group Inc. "The acquisition added infrastructure, talent, and immediate product availability to KRTL’s business model."
In connection with this transaction, KRTL Biotech has already:
Introduced SIGMA's pharmaceutical and nutraceutical products to U.S. and LATAM audiences
Highlighted multiple therapeutic categories through a structured press campaign
Begun regulatory review of U.S. market entry pathways, including OTC Monograph and ANDA considerations
Laid the groundwork for revenue consolidation from SIGMA's operations
Additionally, the Company has continued to advance its regulatory transparency. In Q4 2025, KRTL Holding continues its internal review and content update process to align fully with SEC Rule 15c2-11.
"Regulatory clarity is not optional; it is central to our identity as a company," Herrera added. "We are taking the necessary steps to strengthen our reporting and to ensure shareholders and stakeholders have full insight into our financial and operational progress."
To further this mission, KRTL Holding has formally engaged an external firm to initiate its PCAOB-compliant audit. This audit marks a critical milestone toward potential uplisting initiatives and supports the Company's objective to broaden its access to institutional and strategic capital. This engagement signals KRTL's commitment to transparency, long-term governance, and sustainable growth.
"With SIGMA fully integrated and a PCAOB audit underway, KRTL is not just building products — we're building infrastructure, compliance, and value," Herrera concluded.
https://www.otcmarkets.com/stock/KRTL/news/KR...?id=497103
KRTL Holding Group Inc. (OTC: KRTL) ("KRTL Holding" or the "Company"
today issued a corporate update summarizing recent operational milestones, strategic transactions, and its path forward in public company compliance. In the third quarter of 2025, KRTL Holding successfully closed its strategic merger with Industria Químico-Farmacéutica SIGMA Corp., a Bolivian pharmaceutical manufacturer with over 50 years of continuous operation and a national reputation for quality manufacturing, public health alignment, and product innovation. The deal was finalized in September 2025, and initial integration steps are in process within the first 30 days, including organizational realignment, catalog assessment, and operational audits. The integration of SIGMA under the KRTL Biotech Inc. subsidiary marks a major advancement in the Company’s long-term strategy to build a scalable, international life sciences platform.
"The SIGMA transaction positions KRTL to be more than a U.S. holding company — it makes us an operating force in international pharma," said Cesar Herrera, CEO of KRTL Holding Group Inc. "The acquisition added infrastructure, talent, and immediate product availability to KRTL’s business model."
In connection with this transaction, KRTL Biotech has already:
Introduced SIGMA's pharmaceutical and nutraceutical products to U.S. and LATAM audiences
Highlighted multiple therapeutic categories through a structured press campaign
Begun regulatory review of U.S. market entry pathways, including OTC Monograph and ANDA considerations
Laid the groundwork for revenue consolidation from SIGMA's operations
Additionally, the Company has continued to advance its regulatory transparency. In Q4 2025, KRTL Holding continues its internal review and content update process to align fully with SEC Rule 15c2-11.
"Regulatory clarity is not optional; it is central to our identity as a company," Herrera added. "We are taking the necessary steps to strengthen our reporting and to ensure shareholders and stakeholders have full insight into our financial and operational progress."
To further this mission, KRTL Holding has formally engaged an external firm to initiate its PCAOB-compliant audit. This audit marks a critical milestone toward potential uplisting initiatives and supports the Company's objective to broaden its access to institutional and strategic capital. This engagement signals KRTL's commitment to transparency, long-term governance, and sustainable growth.
"With SIGMA fully integrated and a PCAOB audit underway, KRTL is not just building products — we're building infrastructure, compliance, and value," Herrera concluded.
